264 -5 (79) 2025 - Agababyan I.R., Sattorov U.A. - POSSIBILITIES OF REDUCING THE LEVEL OF PROINFLAMMATORY CYTOKINES IN PATIENTS WHO HAVE UNDERGONE CORONARY ARTERY BYPASS GRAFTING

POSSIBILITIES OF REDUCING THE LEVEL OF PROINFLAMMATORY CYTOKINES IN PATIENTS WHO HAVE UNDERGONE CORONARY ARTERY BYPASS GRAFTING

Agababyan I.R. - Samarkand State Medical University

Sattorov U.A. - Samarkand State Medical University

Resume

The continuous use of low-dose colchicine (0.5 mg per day) is currently approved by the FDA and included in international clinical guidelines for secondary prevention of myocardial infarction, stroke, and cardiovascular death among patients with ischemic heart disease [1,2]. These new recommendations are primarily based on the results of randomized double-blind placebo-controlled trials LoDoCo2 and COLCOT, in which prolonged use of low-dose colchicine safely reduced major adverse cardiovascular events by 31% among contemporary patients with clinically stable atherosclerosis [hazard ratio (HR) 0.69, 95% CI 0.57–0.83, P < 0.001] and by 23% following recent myocardial infarction (HR 0.77, 95% CI 0.61–0.96, P = 0.02) [3,4]. Thus, clinical interest in the use of low-dose colchicine as an adjunct to statin therapy and other pharmacological treatments recommended by guidelines is likely to increase, especially after coronary artery stenting and coronary artery bypass grafting. Since colchicine is excreted by the kidneys, its use should be limited in patients with significant renal impairment according to some authors. However, colchicine itself does not have a negative impact on kidney function. In patients with chronic kidney disease (CKD), colchicine does not increase the risk of dialysis nor shorten the duration of dialysis [5,6].

Keywords: Colchicine, C-reactive protein, coronary artery bypass grafting (CABG), atherosclerosis, ischemic heart disease (IHD), interleukin-6 (IL-6).

First page

1315

Last page

1320

For citation:Agababyan I.R., Sattorov U.A. - POSSIBILITIES OF REDUCING THE LEVEL OF PROINFLAMMATORY CYTOKINES IN PATIENTS WHO HAVE UNDERGONE CORONARY ARTERY BYPASS GRAFTING//New Day in Medicine 5(79)2025 1315-1320 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

1. Nelson K., Fuster V., Ridker P. M. Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week //Journal of the American College of Cardiology. – 2023. – Т. 82. – №. 7. – С. 648-660.
2. Bonaventura A., Abbate A. Colchicine for cardiovascular prevention: the dawn of a new era has finally come. – 2023.
3. Nidorf S. M. et al. Colchicine in patients with chronic coronary disease //New England journal of medicine. – 2020. – Т. 383. – №. 19. – С. 1838-1847.
4. Tardif J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction //New England journal of medicine. – 2019. – Т. 381. – №. 26. – С. 2497-2505.
5. Solak Y. et al. Colchicine in renal medicine: new virtues of an ancient friend //Blood purification. – 2017. – Т. 43. – №. 1-3. – С. 125-135.
6. Nasri H. Colchicine and the concepts of nephroprotection; a new feature of an old drug //Journal of Renal Endocrinology. – 2022. – Т. 8. – №. 1. – С. e25072-e25072.
7. Agababyan, I.R., Kobilova, N.A. Colchicine Effect on C-Reactive Protein Levels in Patients with Coronary Heart Disease after Myocardial Revascularization. Kardiologija v Belarusi, 2023, 15(3), pp. 355–361.

   file

   download